Author's Accepted Manuscript Testosterone Therapy after Radiation Therapy for Low, Intermediate, and High Risk Prostate Cancer Alexander W. Pastuszak , Abhinav Khanna , Niraj Badhiwala , Abraham Morgentaler , Mariam Hult , William P. Conners , Michael F. Sarosdy , Christopher Yang , Rafael Carrion , Larry I. Lipshultz , Mohit Khera PII: DOI: Reference:
S0022-5347(15)04081-1 10.1016/j.juro.2015.05.084 JURO 12651
To appear in: The Journal of Urology Accepted Date: 13 May 2015 Please cite this article as: Pastuszak AW, Khanna A, Badhiwala N, Morgentaler A, Hult M, Conners WP, Sarosdy MF, Yang C, Carrion R, Lipshultz LI, Khera M, Testosterone Therapy after Radiation Therapy for Low, Intermediate, and High Risk Prostate Cancer, The Journal of Urology® (2015), doi: 10.1016/ j.juro.2015.05.084. DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.
Embargo Policy All article content is under embargo until uncorrected proof of the article becomes available online. We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date. Questions regarding embargo should be directed to [email protected].
ACCEPTED MANUSCRIPT
Testosterone Therapy after Radiation Therapy for Low, Intermediate, and High Risk Prostate Cancer
RI PT
Alexander W. Pastuszak1,2, Abhinav Khanna1, Niraj Badhiwala3, Abraham Morgentaler4, Mariam Hult4, William P. Conners4, Michael F. Sarosdy5, Christopher Yang6, Rafael Carrion6, Larry I. Lipshultz1,2, Mohit Khera1 1
Scott Department of Urology, Baylor College of Medicine, Houston, TX Center for Reproductive Medicine, Baylor College of Medicine, Houston, TX 3 Department of Urology, Washington University in St. Louis, St. Louis, IL 4 Harvard Medical School, Boston, MA 5 South Texas Urology and Urologic Oncology, San Antonio, TX 6 Department of Urology, University of South Florida Morsani College of Medicine, Tampa, FL
M AN U
SC
2
TE D
Running Title: Testosterone therapy after radiation therapy
MeSH Key Words: Testosterone therapy, radiation, prostate cancer
EP
Abbreviations: TTh - testosterone therapy, CaP - prostate cancer, RT - radiation therapy, RP – radical prostatectomy, BCR - biochemical recurrence
AC C
Abstract Word Count: 230 Word Count: 2,476
Correspondence: Mohit Khera, MD, MBA, MPH Scott Department of Urology Baylor College of Medicine 7200 Cambridge 10th floor Houston, Texas 77005 Phone (713) 798-6593 Email: [email protected]
ACCEPTED MANUSCRIPT
ABSTRACT Introduction: Limited literature regarding the safety of testosterone (T) therapy (TTh) in men treated for prostate cancer (CaP) exists. Here we present multi-institutional data for
RI PT
TTh in hypogonadal men with CaP treated with radiation therapy (RT).
Methods: A retrospective review of hypogonadal men treated with TTh after RT for CaP at four institutions was performed. Serum testosterone, free T (FT), estradiol (E), sex
prostate biopsy findings were analyzed.
SC
hormone-binding globulin (SHBG), prostate specific antigen (PSA), PSA velocity, and
M AN U
Results: There were 98 men treated with RT, with median age 70.0 years (range 63.0– 74.3) at initiation of TTh. Baseline T levels were 209 (152–263) ng/dL and PSA 0.08 (0.00–0.33) ng/mL. The cohort comprised 3 (3.1%) men with Gleason score (Gl) 5, 44 (44.9%) men with Gl 6, 28 (28.6%) with Gl 7, 7 (7.1%) with Gl 8, and 4 (4.1%) with Gl
TE D
9 tumors. Median duration of follow-up was 40.8 months (range 1.5–147). Serum T increased to 420 ng/dl (231–711) (p
S0022-5347(15)04081-1 10.1016/j.juro.2015.05.084 JURO 12651
To appear in: The Journal of Urology Accepted Date: 13 May 2015 Please cite this article as: Pastuszak AW, Khanna A, Badhiwala N, Morgentaler A, Hult M, Conners WP, Sarosdy MF, Yang C, Carrion R, Lipshultz LI, Khera M, Testosterone Therapy after Radiation Therapy for Low, Intermediate, and High Risk Prostate Cancer, The Journal of Urology® (2015), doi: 10.1016/ j.juro.2015.05.084. DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.
Embargo Policy All article content is under embargo until uncorrected proof of the article becomes available online. We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date. Questions regarding embargo should be directed to [email protected].
ACCEPTED MANUSCRIPT
Testosterone Therapy after Radiation Therapy for Low, Intermediate, and High Risk Prostate Cancer
RI PT
Alexander W. Pastuszak1,2, Abhinav Khanna1, Niraj Badhiwala3, Abraham Morgentaler4, Mariam Hult4, William P. Conners4, Michael F. Sarosdy5, Christopher Yang6, Rafael Carrion6, Larry I. Lipshultz1,2, Mohit Khera1 1
Scott Department of Urology, Baylor College of Medicine, Houston, TX Center for Reproductive Medicine, Baylor College of Medicine, Houston, TX 3 Department of Urology, Washington University in St. Louis, St. Louis, IL 4 Harvard Medical School, Boston, MA 5 South Texas Urology and Urologic Oncology, San Antonio, TX 6 Department of Urology, University of South Florida Morsani College of Medicine, Tampa, FL
M AN U
SC
2
TE D
Running Title: Testosterone therapy after radiation therapy
MeSH Key Words: Testosterone therapy, radiation, prostate cancer
EP
Abbreviations: TTh - testosterone therapy, CaP - prostate cancer, RT - radiation therapy, RP – radical prostatectomy, BCR - biochemical recurrence
AC C
Abstract Word Count: 230 Word Count: 2,476
Correspondence: Mohit Khera, MD, MBA, MPH Scott Department of Urology Baylor College of Medicine 7200 Cambridge 10th floor Houston, Texas 77005 Phone (713) 798-6593 Email: [email protected]
ACCEPTED MANUSCRIPT
ABSTRACT Introduction: Limited literature regarding the safety of testosterone (T) therapy (TTh) in men treated for prostate cancer (CaP) exists. Here we present multi-institutional data for
RI PT
TTh in hypogonadal men with CaP treated with radiation therapy (RT).
Methods: A retrospective review of hypogonadal men treated with TTh after RT for CaP at four institutions was performed. Serum testosterone, free T (FT), estradiol (E), sex
prostate biopsy findings were analyzed.
SC
hormone-binding globulin (SHBG), prostate specific antigen (PSA), PSA velocity, and
M AN U
Results: There were 98 men treated with RT, with median age 70.0 years (range 63.0– 74.3) at initiation of TTh. Baseline T levels were 209 (152–263) ng/dL and PSA 0.08 (0.00–0.33) ng/mL. The cohort comprised 3 (3.1%) men with Gleason score (Gl) 5, 44 (44.9%) men with Gl 6, 28 (28.6%) with Gl 7, 7 (7.1%) with Gl 8, and 4 (4.1%) with Gl
TE D
9 tumors. Median duration of follow-up was 40.8 months (range 1.5–147). Serum T increased to 420 ng/dl (231–711) (p
